Identifying specific groups of patients who may benefit from Alzheimer's treatments
Innovative precision medicine methods in subgroup identification for Alzheimer's disease
This study is looking to find out which groups of people with Alzheimer's might get the most benefit from the new drug aducanumab, so that treatments can be better matched to individual needs and improve their outcomes.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10912813 on NIH RePORTER |
What this research studies
This research focuses on finding specific subgroups of patients with Alzheimer's disease who may benefit from existing treatments, particularly the recently approved drug aducanumab. By using advanced statistical methods, the researchers aim to analyze data from clinical trials to identify characteristics that predict which patients respond best to treatment. This approach could help tailor therapies to individual needs, potentially improving outcomes for those with Alzheimer's. The study will utilize innovative techniques to explore treatment effects across different patient profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease who are seeking treatment options.
Not a fit: Patients with other forms of dementia or those who do not have a diagnosis of Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in identifying subpopulations that respond differently to treatments, suggesting that this approach could yield valuable insights.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Liu, Lei — Washington University
- Study coordinator: Liu, Lei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.